Patents by Inventor Ivelin Georgiev
Ivelin Georgiev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939356Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.Type: GrantFiled: March 15, 2021Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington
-
Publication number: 20230322906Abstract: The present disclosure relates to recombinant antibodies and uses thereof for treating infection.Type: ApplicationFiled: March 16, 2023Publication date: October 12, 2023Inventors: Lauren Walker, Ivelin Georgiev, Andrea R. Shiakolas, Rohit Venkat
-
Publication number: 20230227512Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.Type: ApplicationFiled: October 3, 2022Publication date: July 20, 2023Inventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, John Mascola, Baoshan Zhang, Cheng Cheng, Mallika Sastry, Aliaksandr Druz
-
Patent number: 11459360Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.Type: GrantFiled: August 30, 2019Date of Patent: October 4, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, John Mascola, Baoshan Zhang, Cheng Cheng, Mallika Sastry, Aliaksandr Druz
-
Patent number: 11429845Abstract: Systems and methods for generating regressors based on data sparsity using a machine learning (ML) model are described. A system is configured to provide a plurality of time series datasets to a recurrent neural network (RNN) of a machine learning (ML) model. The RNN generates one or more outputs associated with one or more time series datasets, and the system provides a first portion and a second portion of the one or more outputs to a regressor layer and a classification layer of the ML model, respectively. The regressor layer generates one or more regressors for the one or more time series datasets, and the classification layer generates one or more classifications associated with the one or more regressors (with each indicating whether an associated regressor is valid). Whether a classification indicates a regressor is valid may be based on time series data sparsity.Type: GrantFiled: March 29, 2022Date of Patent: August 30, 2022Assignee: Intuit Inc.Inventors: Ivelin Georgiev Angelov, Yanting Cao, Seid Mohamadali Sadat, Avishek Kumar
-
Publication number: 20220185911Abstract: The present disclosure relates to antibodies and uses thereof for treating lung cancer.Type: ApplicationFiled: April 3, 2020Publication date: June 16, 2022Inventors: Kevin J. KRAMER, Ivelin GEORGIEV
-
Publication number: 20220098286Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: December 14, 2021Publication date: March 31, 2022Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Patent number: 11236152Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: November 3, 2016Date of Patent: February 1, 2022Assignees: The United States of America, as represented by the Sectetary, Department of Health and Human Services, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20210198324Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.Type: ApplicationFiled: March 15, 2021Publication date: July 1, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington
-
Patent number: 10961283Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.Type: GrantFiled: June 27, 2017Date of Patent: March 30, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington
-
Patent number: 10815295Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: GrantFiled: July 24, 2018Date of Patent: October 27, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20190389915Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.Type: ApplicationFiled: August 30, 2019Publication date: December 26, 2019Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, John Mascola, Baoshan Zhang, Cheng Cheng, Mallika Sastry
-
Publication number: 20190330279Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.Type: ApplicationFiled: June 27, 2017Publication date: October 31, 2019Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServiceInventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Rita Chen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Paul Thomas, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington, Kizzmekia Corbett
-
Patent number: 10400015Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.Type: GrantFiled: September 4, 2015Date of Patent: September 3, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Aliaksandr Druz, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, Ulrich Baxa, John Mascola, Rebecca Lynch, Baoshan Zhang, Cheng Cheng
-
Publication number: 20190077849Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: November 3, 2016Publication date: March 14, 2019Applicants: The Trustees of Columbia University in the City of New York, The United States of AMerica, as represented by the Secretary, Department of Health and Human SercInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20190016786Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: ApplicationFiled: July 24, 2018Publication date: January 17, 2019Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Patent number: 10047148Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: September 8, 2017Date of Patent: August 14, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Patent number: 10035844Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: GrantFiled: June 2, 2017Date of Patent: July 31, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20180002406Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: ApplicationFiled: September 8, 2017Publication date: January 4, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Patent number: 9783595Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: August 2, 2016Date of Patent: October 10, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek